Health In Tech, Inc.

STUART, Fla., June 29, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company") was added as a member of the Russell Microcap® Index, effective when the U.S. market opens on June 29, 2026, as part of the 2026 Russell U.S. indexes reconstitution.

prnewswire.com - 2026-06-29 06:00:00

Health In Tech, Inc. (HIT) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-14 09:31:13

Health In Tech NASDAQ: HIT reported first-quarter 2026 revenue growth and a wider loss as management said the company is intentionally increasing investment in sales distribution, carrier relationships and technology development to pursue a larger share of the self-funded health insurance market.

marketbeat.com - 2026-05-13 20:14:29

Reiterates Guidance for 2026 Annual Revenue Ranging between $45 Million and $50 Million STUART, Fla., May 13, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three months ended March 31, 2026.

prnewswire.com - 2026-05-13 16:00:00

STUART, Fla., April 30, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it will release financial results for the first quarter ended March 31, 2026, following the close of market on Wednesday, May 13, 2026.

prnewswire.com - 2026-04-30 16:01:00

FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy PONTE VEDRA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today announced a major regulatory milestone after successfully completing its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the Company's investigational first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT).

globenewswire.com - 2026-04-30 08:30:00

STUART, Fla., April 21, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) (the "Company"), an AI-enabled InsurTech platform company, today announced that it will be participating in the Market Movers Investor Summit on Tuesday, May 5, 2026.

prnewswire.com - 2026-04-21 16:00:00